Ankylosing Spondylitis
Conditions
Interventions
Intervention group:Etanercept 25mg each time, twice a week, with an interval of 3-4 days
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet the program conditions and voluntarily participate in the program.
Exclusion criteria
Exclusion criteria: 1. No response to previous etanercep therapy; known to be allergic to the ingredient etanercep; 2. Patients who are pregnant, breast-feeding, or planning to become pregnant during or after the study, or patients who have fertility requirements; 3. Patients with active infection, including mycobacterium infection and opportunistic infection, within 3 months prior to the first study medication; 4. Get or expected to get vaccinated within 3 months prior to the first treatment, during the study, or within 6 months after the final treatment; 5. Positive for Hepatitis B surface antigen, hepatitis C antibody, or/and human immunodeficiency virus antibody; 6. Symptoms or signs of severe, progressive, or/and uncontrolled kidney, liver, blood, gastrointestinal, endocrine, lung, heart, nerve, mental, or brain diseases; 7. Concurrent heart failure or a history of heart failure, including asymptomatic heart failure; 8. Lymphoproliferative diseases, including lymphoma or signs which suggest lymphoproliferative diseases; 9. Patients with malignant tumor or a history of malignant tumor within 5 years; 10. Patients who underwent an organ transplant.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ASDAS (Ankylosing Spondylitis Disease Activity Scores);ASAS20;ASAS40;The extent and duration of labor constraints;Willingness to pay; | — |
Secondary
| Measure | Time frame |
|---|---|
| The spine X-ray;Blood routine examination;Biochemical detection;Urine routine;C-reactive protein;Erythrocyte sedimentation rate;SF-36 (36-Item Short Form Survey);Visual Analogue Scale (VAS);Morning stiffness duration;Examination fee;Routine treatment fee;Medical treatment fee;Adverse drug event treatmentfee; | — |
Countries
China
Contacts
Public ContactZhao Yi
West China School of Medicine, Sichuan University
Outcome results
None listed